228 related articles for article (PubMed ID: 35083189)
1. Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumor: A Systematic Review.
Feng M; Yang Y; Liao W; Li Q
Front Public Health; 2021; 9():768765. PubMed ID: 35083189
[No Abstract] [Full Text] [Related]
2. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.
Blanke CD; Huse DM
J Med Econ; 2010; 13(4):681-90. PubMed ID: 21067355
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
Wu L; Zhang Z; Yao H; Liu K; Wen Y; Xiong L
Drug Des Devel Ther; 2014; 8():2061-7. PubMed ID: 25378911
[TBL] [Abstract][Full Text] [Related]
4. Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic evaluation.
Hislop J; Quayyum Z; Elders A; Fraser C; Jenkinson D; Mowatt G; Sharma P; Vale L; Petty R
Health Technol Assess; 2011 Jun; 15(25):1-178. PubMed ID: 21689502
[TBL] [Abstract][Full Text] [Related]
5. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.
Wilson J; Connock M; Song F; Yao G; Fry-Smith A; Raftery J; Peake D
Health Technol Assess; 2005 Jul; 9(25):1-142. PubMed ID: 15985189
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours.
Huse DM; von Mehren M; Lenhart G; Joensuu H; Blanke C; Feng W; Finkelstein S; Demetri G
Clin Drug Investig; 2007; 27(2):85-93. PubMed ID: 17217313
[TBL] [Abstract][Full Text] [Related]
7. Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.
Mohammadi M; Gelderblom H
Expert Opin Investig Drugs; 2021 Feb; 30(2):143-152. PubMed ID: 33252274
[No Abstract] [Full Text] [Related]
8. Cost-effectiveness Analysis of Genetic Testing and Tailored First-Line Therapy for Patients With Metastatic Gastrointestinal Stromal Tumors.
Banerjee S; Kumar A; Lopez N; Zhao B; Tang CM; Yebra M; Yoon H; Murphy JD; Sicklick JK
JAMA Netw Open; 2020 Sep; 3(9):e2013565. PubMed ID: 32986105
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib.
Paz-Ares L; García del Muro X; Grande E; González P; Brosa M; Díaz S
Clin Transl Oncol; 2008 Dec; 10(12):831-9. PubMed ID: 19068454
[TBL] [Abstract][Full Text] [Related]
10. The Role of Surgery in Metastatic Gastrointestinal Stromal Tumors.
Keung EZ; Fairweather M; Raut CP
Curr Treat Options Oncol; 2016 Feb; 17(2):8. PubMed ID: 26820287
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
Nishida T; Doi T; Naito Y
Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
[TBL] [Abstract][Full Text] [Related]
12. Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.
Wagner AJ; Agulnik M; Heinrich MC; Mahadevan D; Riedel RF; von Mehren M; Trent J; Demetri GD; Corless CL; Yule M; Lyons JF; Oganesian A; Keer H
Eur J Cancer; 2016 Jul; 61():94-101. PubMed ID: 27156227
[TBL] [Abstract][Full Text] [Related]
13. Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost-effectiveness study.
Zuidema S; Desar IME; van Erp NP; Kievit W
Br J Clin Pharmacol; 2019 Sep; 85(9):1994-2001. PubMed ID: 31112617
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States.
Sanon M; Taylor DC; Parthan A; Coombs J; Paolantonio M; Sasane M
J Med Econ; 2013; 16(1):150-9. PubMed ID: 22762291
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and economic value of adjuvant imatinib for gastrointestinal stromal tumors.
Rutkowski P; Gronchi A
Oncologist; 2013 Jun; 18(6):689-96. PubMed ID: 23709752
[TBL] [Abstract][Full Text] [Related]
16. The economic burden of gastrointestinal stromal tumor (GIST) recurrence in patients who have received adjuvant imatinib therapy.
Guerin A; Sasane M; Gauthier G; Keir CH; Zhdavana M; Wu EQ
J Med Econ; 2015 Mar; 18(3):241-8. PubMed ID: 25422992
[TBL] [Abstract][Full Text] [Related]
17. [Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib].
Nishida T; Omori T; Ueshima S
Gan To Kagaku Ryoho; 2011 May; 38(5):733-7. PubMed ID: 21566432
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness Analysis of Regorafenib for Gastrointestinal Stromal Tumour (GIST) in Germany.
Tamoschus D; Draexler K; Chang J; Ngai C; Madin-Warburton M; Pitcher A
Clin Drug Investig; 2017 Jun; 37(6):525-533. PubMed ID: 28361439
[TBL] [Abstract][Full Text] [Related]
19. Surgical Management of Metastatic Gastrointestinal Stromal Tumors.
Yonkus JA; Alva-Ruiz R; Grotz TE
Curr Treat Options Oncol; 2021 Mar; 22(5):37. PubMed ID: 33743084
[TBL] [Abstract][Full Text] [Related]
20. Advances in adjuvant therapy of gastrointestinal stromal tumors.
Adekola K; Agulnik M
Curr Oncol Rep; 2012 Aug; 14(4):327-32. PubMed ID: 22535506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
